Queensland Stout Whiting Fishery 1991 TO 2002

The stout whiting (Sillago robusta) fishery in southern Queensland is restricted to offshore waters between Caloundra and Sandy Cape in depths ranging between 20 and 50 fathoms. The fishery consists of five licensed trawlers (T4 endorsement). The fishery is managed by means of a ‘industry agreed’ yearly Total Allowable Catch (TAC), which is reviewed annually and divided equally among the vessels. The TAC quota was set at 1000 tonnes for the managed area in 2002. The stout whiting resource was assessed using a newly developed age-structured model, along side with the previous virtual population and surplus production models. The new model was tuned simultaneously to standardised monthly-catch-rates and yearly patterns in the stout whiting catch age-structure. The limit reference point B/K (the ratio of exploitable biomass in 2002 to the exploitable component of the virgin carrying capacity) was estimated to be at about 0.19 (B/K less than 0.2 is generally accepted as high risk of over exploitation). The results from all three models should be viewed cautiously as their uncertainty is high. Given the high uncertainty, any increase in TAC above 1000 t has high risk. In the last four years total catch has varied between 1178 t and 498 t. This year’s assessment has shown no increase in recruitment and biomass after the catch levels of 881 t in 2000 and 855 t in 2002. The management strategy evaluation suggests this years TAC should range between 700t and 900t depending on the target management objectives of risk and yield from the fishery (Table 3.6). This Table 3.6 should be used to guide the decision on TAC setting and to understand how best to compromise the issues of risk (over fishing) and optimising yield (maximising catch and value in the fishery). Summary of the assessment is given in Table 1.1

Fisheries long term monitoring program : summary of tailor (Pomatomus saltatrix) survey results: 1999-2004

Tailor (Pomatomus saltatrix) is a schooling species with a world-wide distribution in subtropical waters that inhabits the coastal waters of southern Australia (Williams 2002). Its distribution in Australian waters ranges from the northern tip of Fraser Island in Queensland to Onslow in Western Australia (Kailola et al. 1993). Queensland commercial and recreational fishers target these schools on ocean beaches between Fraser Island and the New South Wales border, during their annual spawning migration between late winter and spring (Leigh and O’Neill 2004). The estimated harvest of tailor for the commercial sector is 155 t (2004–05), and between 450 and 540 t (2002) by recreational fishers. The Queensland tailor fishery is managed by the Department of Primary Industries and Fisheries under the Fisheries Regulation 1995. The current management arrangements include spatial and seasonal closures, minimum legal size limit, limited commercial entry, annual commercial quota and recreational possession limit. The Long Term Monitoring Program (LTMP) monitors the tailor stock by investigating the length, weight, sex and age of the commercially and recreationally caught tailor from the ocean beach sector. This report presents a summary of the data collected from 1999 to 2004. Since 1999, the LTMP has collected 14 486 tailor with over half of those fish collected from zones not included in the seasonal closures. The modal length frequency of tailor was between 300 and 370 mm for all years, sexes and regions. There was a significant relationship between length and weight of tailor, yet no difference between sex or region. The majority of tailor collected were aged as one and two year olds, with very few tailor collected of age three or older. The growth of tailor was similar for both sexes and all regions. The majority of the length and age frequency data are representative of the recreational ocean beach fishery on Fraser Island, which is only part of the fishery. It is therefore suggested to extend the monitoring of the commercial catch samples and the recreational catch samples to other regions of the sampling area. There were also limited samples collected of tailor larger than 500 mm and at the age of three years or older. Any extension of the program should also focus on acquiring samples of larger fish to help complete the tailor growth curve

Paraphrasing : generating parallel programs using refactoring

Funding: This work has been supported by the European Union grants RII3-CT-2005- 026133 SCIEnce: Symbolic Computing Infrastructure in Europe, IST-2010- 248828 ADVANCE: Asynchronous and Dynamic Virtualisation through performance ANalysis to support Concurrency Engineering, and IST-2011-288570 ParaPhrase: Parallel Patterns for Adaptive Heterogeneous Multicore Systems, and by the UK’s Engineering and Physical Sciences Research Council grant EP/G055181/1 HPC-GAP: High Performance Computational AlgebraRefactoring is the process of changing the structure of a program without changing its behaviour. Refactoring has so far only really been deployed effectively for sequential programs. However, with the increased availability of multicore (and, soon, manycore) systems, refactoring can play an important role in helping both expert and non-expert parallel programmers structure and implement their parallel programs. This paper describes the design of a new refactoring tool that is aimed at increasing the programmability of parallel systems. To motivate our design, we refactor a number of examples in C, C++ and Erlang into good parallel implementations, using a set of formal pattern rewrite rules.Postprin

Angiographic Findings and Outcome in Diabetec Patients Treated With Thrombolytic Therapy for Acute Myocardial Infarction: The GUSTO-I Experience

OBJECTIVES: This study sought to determine whether diabetes mellitus, in the setting of thrombolysis for acute myocardial infarction, affects 1) early infarct-related artery patency and reocclusion rates; and 2) global and regional ventricular function indexes. We also sought to assess whether angiographic or baseline clinical variables, or both, can account for the known excess mortality after myocardial infarction in the diabetic population. BACKGROUND: Mortality after acute myocardial infarction in patients with diabetes is approximately twice that of nondiabetic patients. It is uncertain whether this difference in mortality is due to a lower rate of successful thrombolysis, increased reocclusion after successful thrombolysis, greater ventricular injury or a more adverse angiographic or clinical profile in diabetic patients. METHODS: Patency rates and global and regional left ventricular function were determined in patients enrolled in the GUSTO-I Angiographic Trial. Thirty-day mortality differences between those with and without diabetes were compared. RESULTS: The diabetic cohort had a significantly higher proportion of female and elderly patients, and th

Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia [The Oral Iloprost in severe Leg Ischaemia Study Group]

Two separate studies are described using the same prostacyclin analogue in a similar group of patients. Objectives: to assess the tolerability and efficacy of two dose regimens of oral Iloprost compared with placebo in the treatment of patients with ischaemic ulcers, gangrene or rest pain due to severe arterial disease over a period of 4 weeks (Study A) and one year (Study B). Design: multicentre, placebo controlled, double-blind, randomized prospective studies. Subjects & Methods: 178 (study A) and 624 (study B) patients with trophic skin lesions (ulcers or gangrene) or ischaemic rest pain due to severe arterial disease. To confirm severe arterial disease patients were required to have a systolic ankle Doppler pressure of 70 mmHg or less or a toe systolic Doppler pressure of 50 mmHg or less in one leg.In both studies patients were randomly allocated to three treatment groups: placebo, low dose Iloprost (50\u2013100 g twice a day) or high dose (150\u2013200 g twice a day) In Study A the main outcome measures were tolerability of different doses of Iloprost and death, major amputation, healing of trophic lesions and relief of rest pain at the end of the follow up, which was 5 months after the end of the treatment. In Study B the primary end point was time to major amputation and stroke or death up to 12 months. Secondary pre-defined end points included the combined end point of patients alive without amputation, no trophic skin changes, no rest pain and not on regular analgesics. Results: the proportion of patients who completed the 4-week treatment period in Study A at the intended dose was 58%, 43%, 45% respectively in the placebo, low dose and high dose Iloprost groups. In an intention to treat analysis the proportion of patients who survived without major amputation, ulcers or gangrene and had no rest pain was 11% in the placebo group, 19% in the low dose iloprost group and 28% in the high dose Iloprost group. The pooled Iloprost groups showed a statistically significantly better result than the placebo group (p=0.04), as did the high dose Iloprost group compared to the placebo (p=0.014). In Study B there was no treatment benefit in terms of a primary end point of amputation and death. However the secondary combined end point of patients who survived without a major amputation, ulcers or gangrene and had no rest pain, nor a need for regular analgesia was favourable for Iloprost, with 18% of patients in the placebo group reaching this optimal secondary end point, compared to 23% in the low dose Iloprost group and 26% in the higher dose Iloprost group (p<0.05). Conclusions: oral Iloprost administered for a year showed no clear benefit in patients with advanced severe leg ischaemia (PAOD III and IV). The results obtained with 4 weeks\u2019 treatment in Study A and in previous trials of intravenous Iloprost could not be reproduce